Bruker Names Biotech Entrepreneur and Immunology Expert Eicke Latz to Board of Directors

0
13
Eicke Latz

BILLERICA, Mass.–Bruker Corporation has appointed Dr. Eicke Latz, an internationally recognized immunology researcher and biotechnology entrepreneur, to its Board of Directors, effective January 1, 2027.

Latz, a physician-scientist specializing in innate immunity and inflammation, brings experience in biomedical research, biotechnology company formation and drug development to the Massachusetts-based scientific instruments and life sciences technology company.

He currently serves as Scientific Director of the German Rheumatology Research Center (DRFZ) and Professor of Experimental Rheumatology at Charité Universitätsmedizin Berlin.

Previously, Latz founded and directed the Institute of Innate Immunity at the University of Bonn, where his research contributed to advances in understanding the biological mechanisms underlying inflammation and immune-related diseases.

In addition to his academic career, Latz has co-founded five biotechnology companies: IFM Therapeutics, Odyssey Therapeutics, Metaimmune Therapeutics, DiosCure Therapeutics and Beren Therapeutics.

His entrepreneurial work has focused on translating discoveries in immunology and inflammation into potential new treatments, with several programs advancing from laboratory research into clinical development.

Latz has also held advisory positions involving pharmaceutical companies and government initiatives focused on biotechnology innovation, venture development and commercialization.

Frank H. Laukien, Chairman, President and CEO of Bruker Corporation, said Latz’s scientific and business experience would support the company’s expansion into advanced life sciences research and drug development technologies.

“Eicke brings a rare combination of world-class disease biology leadership, remarkable biopharma entrepreneurial success, and medical institute strategic leadership to our board. As Bruker expands its leadership in post-genomic life-science tools for disease biology research, molecular diagnostics, and biopharma drug discovery and development, Eicke’s scientific-medical vision, biopharma insights, strategic and leadership experience will be very valuable to Bruker.”

Bruker develops scientific instruments and technologies used in biological research, molecular diagnostics and pharmaceutical discovery. The company has increasingly focused on applications involving proteomics, multiomics and spatial biology, areas that help researchers examine proteins, cellular processes and disease mechanisms.

Latz said he sees opportunities for Bruker’s technologies to contribute to advances in medical research and the development of new diagnostic approaches.

“It’s a great honor to join the Board of Directors at Bruker Corporation, a company at the forefront of AI-accelerated, deep functional proteomics, multiomics and spatial biology research,” said Dr. Latz. “I see Bruker as uniquely positioned to enable significant advancements in disease biology research, novel biomarker discovery, and next-generation proteomic molecular diagnostics, and I am very excited to contribute.”

His appointment will add expertise in immunology, biotechnology entrepreneurship and clinical research to Bruker’s Board as the company continues expanding its presence in life sciences technologies.

Leave A Reply

Please enter your comment!
Please enter your name here